Judah Frommer
Stock Analyst at Morgan Stanley
(4.00)
# 568
Out of 5,055 analysts
184
Total ratings
60.45%
Success rate
7.57%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $11.35 | +67.40% | 2 | Nov 14, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $34 → $37 | $35.88 | +3.12% | 1 | Nov 13, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $71 → $101 | $113.62 | -11.11% | 3 | Sep 12, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $20.10 | +29.35% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $26.00 | +65.38% | 2 | May 9, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $11.14 | +115.44% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $30.76 | -28.48% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $10.95 | -45.21% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $90.34 | +17.33% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $15.04 | +132.71% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $2.08 | +525.00% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.25 | +33.33% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.79 | +2,134.64% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.58 | +722.78% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $70.68 | -57.56% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $26.95 | -14.66% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $75.58 | -33.84% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $17.54 | +703.88% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.96 | +127.27% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $38.56 | -42.95% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $4.75 | +47.37% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $9.65 | -17.10% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $77.35 | -40.53% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.82 | +148.23% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $30.33 | +81.34% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $197.40 | -76.70% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $94.07 | -47.91% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $912.59 | -59.46% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $71.24 | -56.49% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $75.13 | +1.16% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $103.15 | +76.44% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $103.67 | +3.21% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $122.89 | -22.70% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $18.12 | -0.66% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $147.72 | -21.47% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $92.66 | -58.99% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $82.58 | -73.36% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $66.10 | -47.05% | 9 | Apr 29, 2020 |
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $11.35
Upside: +67.40%
Zenas BioPharma
Nov 13, 2025
Maintains: Overweight
Price Target: $34 → $37
Current: $35.88
Upside: +3.12%
ABIVAX Société Anonyme
Sep 12, 2025
Maintains: Overweight
Price Target: $71 → $101
Current: $113.62
Upside: -11.11%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $20.10
Upside: +29.35%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $26.00
Upside: +65.38%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $11.14
Upside: +115.44%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $30.76
Upside: -28.48%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $10.95
Upside: -45.21%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $90.34
Upside: +17.33%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $15.04
Upside: +132.71%
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.08
Upside: +525.00%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.25
Upside: +33.33%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.79
Upside: +2,134.64%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.58
Upside: +722.78%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $70.68
Upside: -57.56%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $26.95
Upside: -14.66%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $75.58
Upside: -33.84%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $17.54
Upside: +703.88%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.96
Upside: +127.27%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $38.56
Upside: -42.95%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $4.75
Upside: +47.37%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $9.65
Upside: -17.10%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $77.35
Upside: -40.53%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.82
Upside: +148.23%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $30.33
Upside: +81.34%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $197.40
Upside: -76.70%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $94.07
Upside: -47.91%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $912.59
Upside: -59.46%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $71.24
Upside: -56.49%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $75.13
Upside: +1.16%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $103.15
Upside: +76.44%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $103.67
Upside: +3.21%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $122.89
Upside: -22.70%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $18.12
Upside: -0.66%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $147.72
Upside: -21.47%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $92.66
Upside: -58.99%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $82.58
Upside: -73.36%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $66.10
Upside: -47.05%